on August 21, 2003
Published online before print August 21, 2003, doi: 10.1161/01.ATV.0000092127.16125.E6
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 23, 2003
Accepted on August 8, 2003
Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity
Catherine Léon ;
From the Institut National de la Santé et de la Recherche Médicale U.311, Etablissement Français du Sang-Alsace, 10 rue Spielmann, 67065 Strasbourg Cédex.
* To whom correspondence should be addressed. E-mail: christian.gachet{at}etss.u-strasbg.fr.
Objective--In vivo, activated platelets contribute to the initiation of thrombin generation through the exposure of phosphatidylserine to form a procoagulant catalytic surface and through platelet-leukocyte interactions, which lead to the exposure of leukocyte tissue factor (TF). On the basis of observations that the platelet P2 years1 and P2 years12 receptors both contribute to thrombosis and thrombin formation in an in vivo model of TF-induced thromboembolism, we further characterized the role of these receptors in thrombin generation.
Methods and Results--By using the selective P2 antagonists MRS2179 and AR-C69931MX, the P2 years12 receptor was found to be involved in thrombin-induced exposure of PS on isolated platelets and consequently in TF-induced thrombin formation in platelet-rich plasma. By contrast, the P2 years1 receptor was not involved in phosphatidylserine exposure nor in thrombin generation in platelet-rich plasma. In addition, both receptors were found to contribute to the interactions between platelets and leukocytes mediated by platelet P-selectin exposure, which result in TF exposure at the surface of leukocytes.
Conclusions--Overall, these results point to a differential involvement of the 2 platelet ADP receptors in the generation of thrombin and provide further evidence for the relevance of molecules targeting these receptors as antithrombotic agents.
Key words: P2 receptor • ADP • thrombin generation • thrombosis • platelets
This article has been cited by other articles:
 |
|
 |
|
  S. Srinivasan, F. Mir, J.-S. Huang, F. T. Khasawneh, S. C.-T. Lam, and G. C. Le Breton The P2Y12 Antagonists, 2-Methylthioadenosine 5'-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels J. Biol. Chem., June 12, 2009; 284(24): 16108 - 16117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. Norgard, C. L. Hann, and G. L. Dale Cangrelor Attenuates Coated-Platelet Formation Clinical and Applied Thrombosis/Hemostasis, April 1, 2009; 15(2): 177 - 182. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Hechler, M. Freund, C. Ravanat, S. Magnenat, J.-P. Cazenave, and C. Gachet Reduced Atherosclerotic Lesions in P2Y1/Apolipoprotein E Double-Knockout Mice: The Contribution of Non-Hematopoietic-Derived P2Y1 Receptors Circulation, August 12, 2008; 118(7): 754 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott, and N. von Beckerath Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention Eur. Heart J., June 2, 2008; 29(12): 1504 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Offermanns Activation of Platelet Function Through G Protein-Coupled Receptors Circ. Res., December 8, 2006; 99(12): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ibanez, G. Vilahur, and J. J. Badimon Pharmacology of thienopyridines: rationale for dual pathway inhibition Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G3 - G9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hechler, C. Nonne, E. J. Roh, M. Cattaneo, J.-P. Cazenave, F. Lanza, K. A. Jacobson, and C. Gachet MRS2500 [2-Iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a Potent, Selective, and Stable Antagonist of the Platelet P2Y1 Receptor with Strong Antithrombotic Activity in Mice J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 556 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Dorsam, S. Kim, S. Murugappan, S. Rachoor, H. Shankar, J. Jin, and S. P. Kunapuli Differential requirements for calcium and Src family kinases in platelet GPIIb/IIIa activation and thromboxane generation downstream of different G-protein pathways Blood, April 1, 2005; 105(7): 2749 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Jacobson, S.-K. Kim, S. Costanzi, and Z.-G. Gao PURINE RECEPTORS: GPCR STRUCTURE AND AGONIST DESIGN Mol. Interv., December 1, 2004; 4(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|